Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20 mg Compared to Lansoprazole 30 mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Duodenal Ulcer Subjects With or Without Helicobacter Pylori Infection

Trial Profile

A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20 mg Compared to Lansoprazole 30 mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Duodenal Ulcer Subjects With or Without Helicobacter Pylori Infection

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Nov 2018

At a glance

  • Drugs Vonoprazan (Primary) ; Lansoprazole
  • Indications Duodenal ulcer
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 05 Nov 2018 Planned number of patients changed from 770 to 530.
    • 05 Nov 2018 Planned End Date changed from 30 May 2019 to 7 Jun 2019.
    • 05 Nov 2018 Planned primary completion date changed from 2 May 2019 to 10 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top